Skip to content

13F-HR filed by Bain Capital Life Sciences Investors, LLC

Bain Capital Life Sciences Investors, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 12:30:04 UTC, with 23 holding rows worth $1,489,841,174.

Accession
0001193125-26-462089
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 23 entries on the cover page, a total value of $1,489,841,174 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,489,841,174 with VALUE read as dollars as filed, 13F file number 028-18477. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBain Capital Life Sciences Investors II, LLC 028-20816
  • included managerBain Capital Life Sciences Fund II, L.P. 028-20814
  • included managerBCLS II Investco (GP), LLC 028-22976
  • included managerBCLS II Investco, LP 028-22978
  • included managerBain Capital Life Sciences III General Partner, LLC 028-22975
  • included managerBain Capital Life Sciences Fund III, L.P. 028-22979
  • included managerBain Capital Life Sciences Opportunities III GP, LLC 028-22968
  • included managerBain Capital Life Sciences Opportunities III, LP 028-22966
  • included managerBCLS Fund III Investments GP, LLC 028-25138
  • included managerBCLS Fund III Investments, LP 028-25140
  • included managerBain Capital Life Sciences IV General Partner, LLC 028-26578
  • included managerBain Capital Life Sciences Fund IV, L.P. 028-26577
  • included managerBain Capital Life Sciences Opportunities IV GP, LLC 028-26576
  • included managerBain Capital Life Sciences Opportunities IV, L.P. 028-26575

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
KAILERA THERAPEUTICS INC482931102COMMON STOCK22,583,268$257,900,921dollars as filed
HEARTFLOW INC42238D107COM4,448,158$221,295,861dollars as filed
ADARx Pharmaceuticals, Inc.00654F105Common Stock, par value $0.0001 per share6,728,970$134,175,662dollars as filed
ALKERMES PLCG01767105SHS3,150,985$127,677,912dollars as filed
NEWAMSTERDAM PHARMA CO NVN62509109COMMON STOCK3,806,559$92,575,514dollars as filed
SAVARA INC805111101COM17,600,621$90,819,204dollars as filed
TARSUS PHARMACEUTICALS INC87650L103COMMON STOCK1,096,141$86,167,644dollars as filed
PHARVARIS NVN69605108COMMON STOCK2,475,509$76,919,016dollars as filed
SOLID BIOSCIENCES INC83422E204COMMON STOCK9,808,819$70,917,761dollars as filed
OLEMA PHARMACEUTICALS INC68062P106COM7,085,249$61,216,551dollars as filed
HEMAB THERAPEUTICS HLDGS INC423494103COM SHS1,650,000$50,886,000dollars as filed
CABALETTA BIO INC12674W109COMMON STOCK21,209,188$40,721,641dollars as filed
FREENOME INC35661P100COMMON STOCK2,365,459$37,255,979dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock1,900,000$30,609,000dollars as filed
C4 THERAPEUTICS INC12529R107COM STK7,171,910$23,882,460dollars as filed
X4 PHARMACEUTICALS INC98420X202COMMON STOCK7,967,454$23,105,616dollars as filed
ANNEXON INC03589W102COM4,437,731$18,771,602dollars as filed
ATEA PHARMACEUTICALS INC04683R106COMMON STOCK2,075,639$10,814,079dollars as filed
DISC MEDICINE INC COM254604101Stock141,234$9,245,178dollars as filed
KYVERNA THERAPEUTICS INC501976104COMMON STOCK1,312,000$8,921,600dollars as filed
RAPID MICRO BIOSYSTEMS INC75340L104CLASS A COM8,434,560$8,687,596dollars as filed
XILIO THERAPEUTICS INC98422T209COM664,021$6,009,390dollars as filed
NEWAMSTERDAM PHARMA CO NV-27N62509117WTS99,999$1,264,987dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001193125-26-462089this filing2026-11-16